Phase Forward, SGS Sign Mega Deal
Phase Forward and SGS Life Science Services have extending their existing partnership via a mulit-year, multimillion dollar agreement. SGS has been a Phase Forward customer since 2002 and as an EU-based data management CRO, manges nearly 100 clinical trials, processing over one million CRF pages per year.
The agreement offers SGS' customers the benefits of Phase Forward's solutions including InForm™ Global Trial Management (GTM), Clarix™ Interactive Response Technology (IRT) and Maaguzi Web-based electronic patient reported outcomes (ePRO) and late phase solutions.
“Our customers are looking for an integrated eClinical solution comprising multiple systems,” said Luc Braeken, global director, Biometrics Services, SGS. “The agreement announced today will allow us to respond to customer demand for this integrated solution with innovative product sets from a market leader. This solution is designed to meet the needs of even the most demanding clinical development professional, offering more effective ways to manage clinical operations, help ensure product safety and reduce time-to-market.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
